



Bringing a Biosimilar for Oncology to Market

A CASE STUDY HIGHLIGHTING THE USE OF INJECTABLE PACKAGING FROM EARLY DEVELOPMENT TO COMMERCIALIZATION

Abigail Hisler, *Global Biologics Marketing Director*



THE CHALLENGE

A large Indian biopharmaceuticals company contacted West for a packaging recommendation while in their early-stage development of a monoclonal antibody biosimilar for oncology treatment. The manufacturing of biosimilars is a complex process, requiring extensive controls to ensure not only that the products being developed are high quality, but that they are also similar to the innovator's biologic drug. The company needed a stopper that they could rely on to maintain the high-quality standards needed for the success of their biosimilar and pipeline of future biosimilar products.

THE CONSIDERATIONS

The company wanted to use packaging for its oncology biosimilar that closely resembled what the innovator was using in terms of quality, performance, and appearance. The organization's overall strategy was to bring biosimilars to regulated markets, such as the US and EU, after launching first in emerging regions. Since developed markets often have tighter regulatory scrutiny for approvals, the customer recognized the importance of maintaining the highest quality standards for their drug treatments, which included decisions around their manufacturing process and selection of their packaging needs.

As the company was in early-stage development work, they only needed very small quantities of premium quality stoppers to support their R&D activities. Additionally, they were looking for a supplier they could rely on for: providing technical expertise in biologics packaging and guiding them through the development process; delivering orders quickly; and working closely together to support a successful commercial launch.

THE SOLUTION

The company selected NovaPure® stoppers from West's Ready Pack™ containment solution. West's Ready Pack offering includes ready-to-use stoppers, seals and vials designed to work together as an integrated solution with proven container closure integrity, offered in small quantities for quick delivery. Customers have the flexibility to order the entire containment solution or only the components that they need. This customer's primary need was for a high-quality stopper.

NovaPure stoppers are West's premium line of elastomers, designed specifically for the use of biologics and biosimilars. NovaPure components were developed using Quality by Design principles, an approach recommended by many regulatory agencies for drug and packaging manufacturers when developing products to minimize risks and ensure patient safety. NovaPure stoppers are ready-to-use and fully vision verified, resulting in a consistent high-quality component with the tightest particulate specification of all West components. NovaPure stoppers are produced with FluroTec™ barrier film, which is designed to protect drugs from contamination by providing an effective barrier minimizing interaction between the drug and the closure while maintaining container closure integrity.

As the company was initially focused on R&D activities, they only needed small quantities of stoppers with a fast delivery to accommodate their drug development timelines and key milestones.

(continued on back)

West's Ready Pack containment solution was a perfect choice, with stoppers offered in both serum and lyo designs and in 13mm and 20mm dimensions in ready-to-use small packs, delivered quickly to customers from strategic stock held by West.

Another key benefit of West's Ready Pack containment solution is the ease of transitioning the customer's drug product from clinical development through product launch. The customer transitioned from small scale volume of NovaPure stoppers via West's Ready Pack containment solution to higher volumes needed post commercialization with no additional regulatory requirements. West partners with you on supplying larger volumes from our global manufacturing network as you transition through commercial launch, enabling your biosimilar and its packaging to maintain a consistent profile throughout the drug development cycle.

The company successfully launched its biosimilar for oncology treatment with the NovaPure stopper in India and several other markets and went on to pursue approval of its biosimilar in the US.

After launching a second biosimilar and focusing on increased development of new biosimilars, they made the strategic decision to transition to a platform strategy. They are now using NovaPure stoppers for their two marketed biosimilars, as well as pipeline programs for biosimilars and innovative biologics. The selection of West's Ready Pack containment solution and NovaPure stoppers was an ideal choice for this customer, providing them with the assurance of:

- Protection of their sensitive biosimilars and biologics
- Confidence that the products they provide to patients are contained with high quality packaging
- Compliance needed to meet stringent regulatory requirements for developed markets
- A packaging solution to accommodate all phases of the development timeline and successfully support a launch

Learn more about how West can support your biosimilar or biologic drug development with solutions for your containment needs. Read more about our **West Ready Pack Containment Solution** and **NovaPure stoppers** or **Contact Us** to talk with an Account Manager or Technical Customer Support Representative.



For more information visit [westpharma.com](https://www.westpharma.com)